ASH 2015: New LIM Kinase inhibitor data on AML mutations with high unmet medical need
During the 57th American Society of Hematology Congress held in Orlando, the teams from U. of Indiana Wells Center led by Pr Kapur and Institut Albert Bonniot led by Dr Lafanechère presented the results of their work in the session dedicated to Oncogene and Tumor Suppressors in Myeloïd malignancies. This new data reinforces the rationale for looking into LIM Kinase inhibition to stop downstream oncogene signaling of specific mutations of Tyrosine Kinase Receptors.
CELLIPSE is developing selective and highly potent LIM Kinase small molecule inhibitors to bring new targeted therapies against cancer indications with poor overall prognosis and high medical need such as Acute Myeloïd Leukemia and Myeloproloferative Neoplasms.
The abstract of the presentation can be consulted in Blood Journal’s special edition.